Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$72.71 ▲ +0.02
(+0.03%)
MKT CAP: $11.40B • VOL: 2.89M
52W L $43 52W H $73
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$61
MEDIAN
$81
MEAN
$83
HIGH
$99
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TECH TAPE
TECH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $87.98 | $83.62 | 2025-02-14 | $66.17 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $91.61 | $85.80 | 2025-02-06 | $68.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $82.89 | $79.98 | 2025-01-29 | $69.80 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $74.16 | — | 2025-01-17 | $71.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $63.98 | $69.07 | 2025-01-09 | $64.71 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $86.52 | $75.62 | 2024-12-18 | $63.26 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $70.53 | $73.44 | 2024-12-04 | $67.62 | -4.3% | 48% | C |